Skip to main content

Labetalol Dosage

Medically reviewed by Last updated on Aug 1, 2023.

Applies to the following strengths: 5 mg/mL; 100 mg; 300 mg; 200 mg; 100 mg/100 mL-NaCl 0.72%; 200 mg/200 mL-NaCl 0.72%; 300 mg/300 mL-NaCl 0.72%; 200 mg/200 mL-D5%; 200 mg/200 mL-NaCl 0.9%; 500 mg/500 mL-NaCl 0.9%

Usual Adult Dose for:

Additional dosage information:

Usual Adult Dose for Hypertension

Initial dose: 100 mg orally 2 times a day (alone or added to a diuretic regimen)
Titration: Dosage may be increased in increments of 100 mg orally 2 times a day every 2 or 3 days
Maintenance dose: 200 to 400 mg orally 2 times a day
Maximum dose: Some patients may require 1200 to 2400 mg orally per day (titration increments should not exceed 200 mg orally 2 times a day)


  • Immediately before the injection and at 5 and 10 minutes after injection, supine blood pressure should be measured to evaluate response.
  • Initial dose: 20 mg by slow IV injection over a 2-minute period
  • Additional injections of 40 to 80 mg can be given at 10 minute intervals until a desired supine blood pressure is achieved or a total of 300 mg has been used
  • The maximum effect usually occurs within 5 minutes of each injection
  • The solution for injection should be prepared according to the manufacturer suggested guidelines for a resultant solution of 1 mg/mL or 2 mg/3 mL:
  • For 1 mg/mL, the diluted solution should be administered at a rate of 2 mL/min to deliver 2 mg/min.
  • For 2 mg/3 mL, the diluted solution should be administered at a rate of 3 mL/min to deliver approximately 2 mg/min.
  • Rate of infusion: The rate of infusion of the diluted solution may be adjusted according to the blood pressure response, at the discretion of the physician. To facilitate a desired rate of infusion, the diluted solution can be infused using a controlled administration mechanism, (e.g., graduated burette or mechanically driven infusion pump).
  • Since the half-life of this drug is 5 to 8 hours, steady-state blood levels (in the face of a constant rate of infusion) would not be reached during the usual infusion time period; the infusion should be continued until a satisfactory response is obtained and should then be stopped and the oral formulation should be started.
  • The effective IV dose is usually in the range of 50 to 200 mg.
  • A total dose of up to 300 mg IV may be required in some patients.

  • The injection solution is intended for IV use in hospitalized patients.
  • Patients should always be kept in a supine position during the period of IV drug administration. A substantial fall in blood pressure on standing should be expected in these patients.
  • Blood pressure should be monitored during and after completion of the infusion or IV injections.

Initiation of Dosing with Labetalol Hydrochloride Tablets After Repeated IV Injections or Slow IV Injection:
  • Subsequent oral dosing with the tablet formulation should begin when it has been established that the supine diastolic blood pressure has begun to rise.
  • The recommended initial dose is 200 mg orally, followed in 6 to 12 hours by an additional dose of 200 or 400 mg orally, depending on the blood pressure response.
  • Thereafter, inpatient titration with labetalol hydrochloride tablets may proceed as follows:
Day 1: 400 mg orally in 2 to 3 divided doses
Day 2: 800 mg orally in 2 to 3 divided doses
Day 3: 1600 mg orally in 2 to 3 divided doses
Day 4: 2400 mg orally in 2 to 3 divided doses

  • While in the hospital, the dosage of the tablets may be increased at 1 day intervals to achieve the desired blood pressure reduction.

Use: For control of blood pressure in severe hypertension

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available


This drug is not removed by hemodialysis or peritoneal dialysis; a supplemental dose is not needed.

Other Comments

Storage requirements:

  • Consult the manufacturer product information.

Reconstitution/preparation techniques:
  • Consult the manufacturer product information.

IV compatibility:
  • Consult the manufacturer product information.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.